TTR Stabilisation

The more stable, the more able.*

// Deposition of amyloid fibrils

The underlying cause of ATTR-CM

Transthyretin (TTR) is a tetrameric protein highly conserved through vertebrate evolution and involved in various physiological functions, including:

  • Transport of thyroid hormone and retinol (vitamin A)
  • Providing neuroprotection
  • Supporting cognitive performance and memory
     

However, when the stability of TTR is compromised, misfolded TTR monomers can aggregate and form amyloid fibrils, which deposit in various organs. When amyloid fibrils deposit in the heart walls, symptoms like shortness of breath, fatigue, and dizziness can occur. Eventually, these deposits can lead to transthyretin amyloid cardiomyopathy
(ATTR-CM).

About ATTR-CM
Discover more details of this progressive cardiomyopathy.
Why TTR matters
Explore why serum TTR levels are an indicator of stability.
Assess ATTR-CM
Find out more about the impact of early diagnosis.

* Within the general population, higher serum TTR (mg/dL) levels and increased TTR stabilisation are linked to a reduced risk of heart failure (R2=0.84).

    • 1
      Liz MA, et al. Neurol Ther. 2020;9(2):395–402.
    • 2
      Vieira M, Saraiva MJ. BioMol Concepts. 2014;5(1):45–54.
    • 3
      Hood CJ, et al. Curr Heart Fail Rep. 2022;19(5):356–363.
    • 4
      Taylor AIP, Staniforth RA. Front Neurosci. 2022;16:878869.
    • 5
      Garcia-Pavia P, et al. Eur J Heart Fail. 2021;23(4):512–526.
    • 6
      Jain A, Zahra F. Transthyretin Amyloid Cardiomyopathy (ATTR-CM). 2023 Apr 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. PMID: 34662045.
    • 7
      Greve AM, et al. JAMA Cardiol. 2021;6(3):258–266.